Article
Biochemistry & Molecular Biology
Joris van de Haar, Xuhui Ma, Salo N. Ooft, Pim W. van der Helm, Louisa R. Hoes, Sara Mainardi, David J. Pinato, Kristi Sun, Lisa Salvatore, Giampaolo Tortora, Ina Valeria Zurlo, Silvana Leo, Riccardo Giampieri, Rossana Berardi, Fabio Gelsomino, Valeria Merz, Federica Mazzuca, Lorenzo Antonuzzo, Gerardo Rosati, Chara Stavraka, Paul Ross, Maria Grazia Rodriquenz, Michele Pavarana, Carlo Messina, Timothy Iveson, Federica Zoratto, Anne Thomas, Elisabetta Fenocchio, Margherita Ratti, Ilaria Depetris, Massimiliano Cergnul, Cristina Morelli, Michela Libertini, Alessandro Parisi, Michele De Tursi, Nicoletta Zanaletti, Ornella Garrone, Janet Graham, Raffaella Longarini, Stefania Maria Gobba, Angelica Petrillo, Emiliano Tamburini, Nicla La Verde, Fausto Petrelli, Vincenzo Ricci, Lodewyk F. A. Wessels, Michele Ghidini, Alessio Cortellini, Emile E. Voest, Nicola Valeri
Summary: Genomic analysis identified KRAS(G12) mutations as potential biomarkers of resistance to trifluridine/tipiracil treatment in metastatic colorectal cancer. Real-world data and phase 3 clinical trial data confirmed the significant association between KRAS(G12) mutations and reduced overall survival. These findings provide important implications for precision medicine in approximately 28% of patients with metastatic colorectal cancer.
Article
Oncology
Yoshinori Takeda, Yoshihiro Mise, Yu Takahashi, Hiromichi Ito, Yosuke Inoue, Ryuji Yoshioka, Yoshihiro Ono, Akio Saiura
Summary: The study found that in patients undergoing hepatectomy for colorectal liver metastases, the prognostic value of the KRAS gene depends on whether patients received preoperative chemotherapy or their tumor burden.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Rona Yaeger, Jared Weiss, Meredith S. Pelster, Alexander Spira, Minal Barve, Sai-Hong Ou, Ticiana A. Leal, Tanios S. Bekaii-Saab, Cloud P. Paweletz, Grace A. Heavey, James G. Christensen, Karen Velastegui, Thian Kheoh, Hirak Der-Torossian, Samuel J. Klempner
Summary: In this study, the researchers investigated the clinical efficacy of adagrasib in combination with cetuximab for heavily pretreated patients with metastatic colorectal cancer harboring mutant KRAS G12C. The results showed that the overall response rate was 19% in the adagrasib monotherapy group, with a median progression-free survival of 5.6 months, and 46% in the combination therapy group, with a median progression-free survival of 6.9 months. Both groups experienced reversible adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Sora Kang, Myung-Won Lee, Ik-Chan Song, Hyo-Jin Lee, Hwan-Jung Yun, Deog-Yeon Jo, Jung Sun Kim, Jung Hye Kwon, Ji-Yeon Kim, Kyung-Ha Lee, Hyewon Ryu
Summary: We retrospectively analyzed the clinical outcomes of patients with metastatic colorectal cancer (mCRC) who received first-line oxaliplatin-based induction chemotherapy with either cetuximab or bevacizumab, and underwent maintenance therapy without oxaliplatin. The disease control rates of maintenance therapy were 79% and 74% in the cetuximab and bevacizumab groups, respectively.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Hyoun Wook Lee, Boram Song, Kyungneun Kim
Summary: The presence of a residual adenoma component in colorectal cancer is associated with a high frequency of KRAS mutation and indolent clinicopathological features. The discordance in the incidence of KRAS mutation between the adenoma and carcinoma components emphasizes the need to document the adenoma component in the pathology report and avoid including it in molecular testing samples.
Article
Oncology
Michel Ducreux, Josep Tabernero, Axel Grothey, Dirk Arnold, Peter J. O'Dwyer, Frank Gilberg, Alexander Abbas, Meghna Das Thakur, Hen Prizant, Natsumi Irahara, Anila Tahiri, Hans -Joachim Schmoll, Eric Van Cutsem, Aimery de Gramont
Summary: This study aimed to explore the feasibility of biomarker-driven maintenance therapy in patients with metastatic colorectal cancer. The findings suggest that vemurafenib plus cetuximab plus 5-FU/LV may be further investigated as first-line maintenance treatment for BRAF(mut) mCRC. However, cobimetinib plus atezolizumab had an unfavorable benefit:risk ratio in HER2-/MSS/BRAF(wt) mCRC.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Medicine, General & Internal
Marwan G. Fakih, Lisa Salvatore, Taito Esaki, Dominik P. Modest, David P. Lopez-Bravo, Julien Taieb, Michalis V. Karamouzis, Erika Ruiz-Garcia, Tae-Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun-Huei Yeh, Emily Chan, Joseph Chao, Yaneth Saportas, Qui Tran, Chiara Cremolini, Filippo Pietrantonio
Summary: In this study, the combination of KRAS G12C inhibitor sotorasib and EGFR inhibitor panitumumab showed longer progression-free survival compared to standard treatment in patients with chemorefractory metastatic colorectal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Chunlong Huang, Xiaoyuan Gu, Xianshang Zeng, Baomin Chen, Weiguang Yu, Meiji Chen
Summary: The study demonstrated that CET showed superior survival benefit compared to BEV, with fewer tolerable adverse events.
Article
Oncology
Iris van 't Erve, Nina J. Wesdorp, Jamie E. Medina, Leonardo Ferreira, Alessandro Leal, Joost Huiskens, Karen Bolhuis, Jan-Hein T. M. van Waesberghe, Rutger-Jan Swijnenburg, Daan van den Broek, Victor E. Velculescu, Geert Kazemier, Cornelis J. A. Punt, Gerrit A. Meijer, Remond J. A. Fijneman
Summary: Patients with mCRC carrying a KRAS A146 mutation have higher tumor burden and worse clinical outcomes, and may benefit from more intensive treatments.
JCO PRECISION ONCOLOGY
(2021)
Article
Virology
XuSha Zhou, Jing Zhao, Jian V. Zhang, Yinglin Wu, Lei Wang, Xiaoqing Chen, Dongmei Ji, Grace Guoying Zhou
Summary: This study demonstrated that MEK inhibitor Trametinib can enhance oncolytic virus activity in BRAF V600E-mutated tumor cells, and combination therapy with oHSV and MEKi Trametinib can improve virus replication and show synergistic therapeutic efficacy in vivo for BRAF or KRAS-mutated tumors, providing new insights for clinical development.
Article
Oncology
Jiawei Zhou, Quefeng Li, Yanguang Cao
Summary: The response of metastatic lesions varies across different anatomic sites and therapies. High interlesion heterogeneity is associated with shorter survival, highlighting the potential benefits of targeted therapies in reducing heterogeneity and improving efficacy. Favorable responses in liver metastases are linked to extended overall survival, while lesions in other organs show less favorable outcomes.
Article
Biochemistry & Molecular Biology
Aleksandr S. Martianov, Natalia V. Mitiushkina, Anastasia N. Ershova, Darya E. Martynenko, Mikhail G. Bubnov, Priscilla Amankwah, Grigory A. Yanus, Svetlana N. Aleksakhina, Vladislav I. Tiurin, Aigul R. Venina, Aleksandra A. Anuskina, Yuliy A. Gorgul, Anna D. Shestakova, Mikhail A. Maidin, Alexey M. Belyaev, Liliya S. Baboshkina, Aglaya G. Iyevleva, Evgeny N. Imyanitov
Summary: This study analyzed the factors influencing the distribution of actionable genetic alterations in colorectal carcinomas. The study found that there were differences in the distribution of certain genetic alterations based on patients' age and gender. BRAF mutation frequency also showed geographic variation. In addition, a small fraction of CRCs had simultaneous alterations in more than one driver gene.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Elena Elez, Javier Ros, Jose Fernandez, Guillermo Villacampa, Ana Belen Moreno-Cardenas, Carlota Arenillas, Kinga Bernatowicz, Raquel Comas, Shanshan Li, David Philip Kodack, Roberta Fasani, Ariadna Garcia, Javier Gonzalo-Ruiz, Alejandro Piris-Gimenez, Paolo Nuciforo, Grainne Kerr, Rossana Intini, Aldo Montagna, Marco Maria Germani, Giovanni Randon, Ana Vivancos, Ron Smits, Diana Graus, Raquel Perez-Lopez, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio, Rodrigo Dienstmann, Josep Tabernero, Rodrigo A. Toledo
Summary: In colorectal cancer patients, inactivating mutations in the RNF43 gene are associated with patients' response rates and survival outcomes to anti-BRAF/EGFR therapy. This suggests that the status of the RNF43 gene may serve as a predictive biomarker for patients' clinical outcomes.
Article
Biochemistry & Molecular Biology
Yi Cheng Chu, Tung-Yao Tsai, Vijesh Kumar Yadav, Li Deng, Chun-Chih Huang, Yew-Min Tzeng, Chi-Tai Yeh, Ming-Yao Chen
Summary: The study demonstrates that 4-AAQB effectively inhibits KRAS-mutant CRC cells, making them resensitized to cetuximab by reducing colony formation, invasion, tumorsphere generation, and oncogenic KRAS signaling pathway.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Jonathan M. Loree, Yucai Wang, Muddassir A. Syed, Alexey Sorokin, Oluwadara Coker, Joanne Xiu, Benjamin A. Weinberg, Ari M. Vanderwalde, Anteneh Tesfaye, Victoria M. Raymond, Benjamin Miron, Gabi Tarcic, Ori Zelichov, Russell R. Broaddus, Patrick Kwok Shing Ng, Kang Jin Jeong, Yiu Huen Tsang, Gordon B. Mills, Michael J. Overman, Axel Grothey, John L. Marshall, Scott Kopetz
Summary: The study identified a high prevalence of atypical RAS mutations in colorectal cancer patients, which were associated with poor prognosis. Activating atypical variants were the most common in clinical cohorts, providing the best evidence to guide treatment.
CLINICAL CANCER RESEARCH
(2021)
Article
Nutrition & Dietetics
Andrei Ivashynka, Maurizio A. Leone, Nadia Barizzone, Aliona Cucovici, Roberto Cantello, Domizia Vecchio, Miriam Zuccala, Alessandro Pizzino, Massimiliano Copetti, Sandra D'Alfonso, Andrea Fontana
Summary: This study aimed to assess the impact of lifetime coffee and tea consumption on the severity of Multiple Sclerosis (MS). The results showed that coffee or tea intake was not associated with different severity of MS, although higher doses of coffee may have an effect on the subgroup of progressive patients.
CLINICAL NUTRITION ESPEN
(2022)
Article
Endocrinology & Metabolism
Maria Giovanna Scarale, Mario Mastroianno, Cornelia Prehn, Massimiliano Copetti, Lucia Salvemini, Jerzy Adamski, Salvatore De Cosmo, Vincenzo Trischitta, Claudia Menzaghi
Summary: This study investigated the association between serum metabolites and all-cause mortality in type 2 diabetes. Hexanoylcarnitine, kynurenine, and tryptophan were found to be significantly associated with mortality. The kynurenine-to-tryptophan ratio (KTR) mediated the association between the antiatherogenic interleukin (IL) 13 and mortality. Adding these three metabolites improved the accuracy and classification of mortality prediction models.
Article
Clinical Neurology
Katina Aleksovska, Teia Kobulashvili, Joao Costa, Georg Zimmermann, Karen Ritchie, Carola Reinhard, Luca Vignatelli, Alessandra Fanciulli, Maxwel Damian, Lucia Pavlakova, Jean-Marc Burgunder, Svetlana Kopishinskaya, Martin Rakusa, Norbert Kovacs, Fusun Ferda Erdogan, Lori Renna Linton, Massimiliano Copetti, Costanza Lamperti, Serenella Servidei, Theresina Evangelista, Segolene Ayme, Davide Pareyson, Johann Sellner, Christian Krarup, Marianne de Visser, Peter van den Bergh, Antonio Toscano, Holm Graessner, Thomas Berger, Claudio Bassetti, Marie Vidailhet, Eugene Trinka, Guenther Deuschl, Antonio Federico, Maurizio A. Leone
Summary: This article introduces the impact of rare diseases on patients and the existing problems within the European Union. It also provides recommendations and methods for developing and reporting high-quality clinical practice guidelines (CPGs) for rare neurological diseases (RNDs). Through a consensus procedure, 63 final items were identified. These recommendations provide solutions to the specific issues of RNDs and are considered as a starting point for further harmonization and improving the quality of CPGs.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Editorial Material
Oncology
Francesca Pirini, Daniele Vergara, Paola Parrella
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
D. Ciardiello, C. Chiarazzo, V Famiglietti, A. Damato, C. Pinto, M. G. Zampino, G. Castellano, L. Gervaso, A. Zaniboni, E. Oneda, S. Rapisardi, R. Bordonaro, C. Zichi, F. De Vita, M. Di Maio, A. Parisi, R. Giampieri, R. Berardi, D. Lavacchi, L. Antonuzzo, E. Tamburini, B. A. Maiorano, P. Parrella, T. P. Latiano, N. Normanno, A. De Stefano, A. Avallone, G. Martini, S. Napolitano, T. Troiani, E. Martinelli, F. Ciardiello, E. Maiello
Summary: Patients with KRASG12C-mutant mCRC have a poor response to standard treatments, and first-line chemotherapy intensification is recommended for fit patients.
Article
Endocrinology & Metabolism
Ernesto Maddaloni, Lucia Coraggio, Rocco G. Amendolara, Marco G. Baroni, Maria Cavallo, Massimiliano Copetti, Efisio Cossu, Paola D'Angelo, Luca D'Onofrio, Salvatore De Cosmo, Frida Leonetti, Susanna Morano, Lelio Morviducci, Nicola Napoli, Sabrina Prudente, Giuseppe Pugliese, Kyoungmin R. Park, Rury Holman, Vincenzo Trischitta, Raffaella Buzzetti, UMMER Study Diabet Grp
Summary: This study evaluated the possible associations of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease (CVD) and diabetic retinopathy (DR) in type 2 diabetes patients. The findings showed that osteocalcin was associated with CVD, while osteoprotegerin and osteopontin were associated with DR.
DIABETES-METABOLISM RESEARCH AND REVIEWS
(2023)
Article
Health Care Sciences & Services
Thomas P. A. Debray, Gabrielle Simoneau, Massimiliano Copetti, Robert W. Platt, Changyu Shen, Fabio Pellegrini, Carl de Moor
Summary: Real-world data sources provide opportunities to compare treatment effectiveness in practical clinical settings, but relevant outcomes are often selectively recorded and collected at irregular times. This study proposes an extension of multilevel multiple imputation methods to analyze real-world outcome data collected at irregular observation times. The multilevel multiple imputation approach is shown to produce less biased treatment effect estimates and improve the coverage of confidence intervals, even when outcomes are missing not at random.
STATISTICAL METHODS IN MEDICAL RESEARCH
(2023)
Article
Oncology
Davide Ciardiello, Stefania Napolitano, Vincenzo Famiglietti, Lucia Esposito, Vincenzo De Falco, Alessandra Di Liello, Antonio Avallone, Evaristo Maiello, Filippo Pietrantonio, Chiara Cremolini, Maria Giulia Zampino, Nicola Fazio, Teresa Troiani, Erika Martinelli, Fortunato Ciardiello, Giulia Martini
Summary: Rechallenge with EGFR inhibitors is a promising strategy in refractory RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients. The presence of plasma ctDNA RAS/BRAF mutations at pretreatment liquid biopsy analysis was not associated with the length of anti-EGFR drug-free interval. Liquid biopsy can be used to select suitable patients for EGFR inhibitor rechallenge.
Article
Medicine, General & Internal
Carla Maria Irene Quarato, Elisa Dama, Michele Maggi, Beatrice Feragalli, Cristina Borelli, Anna Del Colle, Marco Taurchini, Evaristo Maiello, Salvatore De Cosmo, Donato Lacedonia, Maria Pia Foschino Barbaro, Giovanna Elisiana Carpagnano, Giulia Scioscia, Paolo Graziano, Rosalinda Termine, Elisabettamaria Frongillo, Sonia Santamaria, Mariapia Venuti, Maria Arcangela Grimaldi, Stefano Notarangelo, Annarita Saponara, Massimiliano Copetti, Tommaso Colangelo, Roberto Cuttano, Dimitrios Macrodimitris, Francesco Mazzarelli, Michela Talia, Antonio Mirijello, Luca Pazienza, Rita Perna, Anna Simeone, Doriana Vergara, Antonio Varriale, Massimo Carella, Fabrizio Bianchi, Marco Sperandeo
Summary: This study validated a screening protocol using thoracic ultrasound (TUS) as a first-line complementary imaging technique to select patients for a second-line low-dose high resolution computed tomography (HRCT) scan. The study focused on a population of asymptomatic high-risk subjects for interstitial lung abnormalities (ILA) and lung cancer in the Tamburi district of Taranto. The results showed that TUS had a diagnostic accuracy of 88.6% in detecting pleuro-pulmonary abnormalities compared to HRCT scan, with a sensitivity of 95.3% and a specificity of 81.7%.
FRONTIERS IN MEDICINE
(2023)
Article
Infectious Diseases
Antonio Mirijello, Andrea Fontana, Antonio Pio Greco, Alberto Tosoni, Angelo D'Agruma, Maria Labonia, Massimiliano Copetti, Pamela Piscitelli, Salvatore De Cosmo
Summary: This study aimed to identify prognostic predictors of death or admission to intensive care units in septic patients. Different statistical models and machine learning algorithms identified similar predictive variables, including SOFA score, delta SOFA, and AVPU status.
Article
Medicine, General & Internal
Carla Maria Irene Quarato, Beatrice Feragalli, Donato Lacedonia, Gaetano Rea, Giulia Scioscia, Evaristo Maiello, Concetta Di Micco, Cristina Borelli, Antonio Mirijello, Paolo Graziano, Lucia Dimitri, Rosanna Villani, Marco Sperandeo
Summary: This study aimed to examine the efficacy of pulmonary contrast-enhanced ultrasound (CEUS) in differentiating between malignant and benign peripheral lung lesions. The results showed that the dynamic parameters of CEUS cannot effectively differentiate between the two types of lesions.
Article
Medicine, General & Internal
Paolo Bironzo, Francesco Pepe, Gianluca Russo, Pasquale Pisapia, Gianluca Gragnano, Gabriella Aquino, Silvia Bessi, Simonetta Buglioni, Federico Bartoccini, Giuseppina Ferrero, Michela Anna Bresciani, Paola Francia di Celle, Francesca Sibona, Andrea Giusti, Alessandra Movilia, Renata Mariella Farioli, Alessandra Santoro, Domenico Salemi, Stefania Scarpino, Dino Galafate, Stefania Tommasi, Rosanna Lacalamita, Davide Seminati, Elham Sajjadi, Silvia Novello, Fabio Pagni, Giancarlo Troncone, Umberto Malapelle
Summary: Lung cancer is the leading cause of cancer deaths worldwide. The molecular analysis of MET proto-oncogene, receptor tyrosine kinase (MET) exon 14 skipping has been promoted for the stratification of non-small cell lung cancer (NSCLC) patients. Different testing strategies for MET exon 14 skipping were evaluated for their technical performance and reproducibility in various centers. The use of artificial reference slides proved to be a valid tool for harmonizing technical workflows in the evaluation of MET exon 14 skipping molecular alterations in routine practice.
Editorial Material
Endocrinology & Metabolism
Vincenzo Trischitta, Claudia Menzaghi, Massimiliano Copetti
Article
Endocrinology & Metabolism
Massimiliano Copetti, Marco Giorgio Baroni, Raffaella Buzzetti, Maria Gisella Cavallo, Efiso Cossu, Paola D'Angelo, Salvatore De Cosmo, Frida Leonetti, Susanna Morano, Lelio Morviducci, Nicola Napoli, Sabrina Prudente, Giuseppe Pugliese, Antonio Fernando Savino, Vincenzo Trischitta
Summary: This study aimed to validate the association of a 14-metabolite score with all-cause mortality in type 2 diabetes and explore whether it could improve existing mortality prediction models. The results showed a significant association between the 14-metabolite score and mortality in type 2 diabetes, although the effect size was lower compared to the general population. However, a simplified version of the score without two specific metabolites improved patient analysis and classification of mortality risk.
DIABETES-METABOLISM RESEARCH AND REVIEWS
(2023)
Article
Endocrinology & Metabolism
Vincenzo Trischitta, Mario Mastroianno, Maria Giovanna Scarale, Cornelia Prehn, Lucia Salvemini, Andrea Fontana, Jerzy Adamski, Francesco Paolo Schena, Salvatore De Cosmo, Massimiliano Copetti, Claudia Menzaghi
Summary: This study investigated the association between 188 serum metabolites and kidney function in type 2 diabetes. Ten metabolites were found to be independently associated with low estimated glomerular filtration rate (eGFR), and five metabolites were associated with eGFR decline. Two of these metabolites improved clinical prediction models for GFR decline in individuals with diabetes.
BMJ OPEN DIABETES RESEARCH & CARE
(2023)